These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16377176)

  • 1. Specific peptides for the therapeutic targeting of oncogenes.
    Privé GG; Melnick A
    Curr Opin Genet Dev; 2006 Feb; 16(1):71-7. PubMed ID: 16377176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
    Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
    J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a tumor-homing cell-penetrating peptide.
    Myrberg H; Zhang L; Mäe M; Langel U
    Bioconjug Chem; 2008 Jan; 19(1):70-5. PubMed ID: 18001077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current strategies for the development of peptide-based anti-cancer therapeutics.
    Borghouts C; Kunz C; Groner B
    J Pept Sci; 2005 Nov; 11(11):713-26. PubMed ID: 16138387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
    Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
    J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades.
    Bidwell GL; Raucher D
    Expert Opin Drug Deliv; 2009 Oct; 6(10):1033-47. PubMed ID: 19637980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinatorial discovery of tumor targeting peptides using phage display.
    Landon LA; Deutscher SL
    J Cell Biochem; 2003 Oct; 90(3):509-17. PubMed ID: 14523985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides.
    Raucher D; Moktan S; Massodi I; Bidwell GL
    Expert Opin Drug Deliv; 2009 Oct; 6(10):1049-64. PubMed ID: 19743895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Hsp90 for the treatment of cancer.
    Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purine-scaffold Hsp90 inhibitors.
    Chiosis G; Tao H
    IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designed TPR modules as novel anticancer agents.
    Cortajarena AL; Yi F; Regan L
    ACS Chem Biol; 2008 Mar; 3(3):161-6. PubMed ID: 18355005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.
    Okarvi SM
    Cancer Treat Rev; 2008 Feb; 34(1):13-26. PubMed ID: 17870245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
    Huq A; Singh B; Meeker T; Mascarenhas D
    Anticancer Drugs; 2009 Jan; 20(1):21-31. PubMed ID: 19342998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C
    Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect.
    Orosz A; Szabo A; Szeman G; Janaky T; Somlai C; Penke B; Bodor A; Perczel A
    Int J Biochem Cell Biol; 2006; 38(8):1352-62. PubMed ID: 16540363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.